Egetis publishes corporate presentation on Emcitate launch, FDA review for MCT8 deficiency drug

Reuters2026/08/05 12:59

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Egetis Therapeutics highlighted Emcitate (tiratricol) as its lead product for MCT8 deficiency, with EU approval in Feb 2025.
Germany launch started in May 2025; the company targets a phased rollout across Europe, starting with the EU4 markets.
FDA accepted the Emcitate NDA for priority review on March 27, 2026; PDUFA date set for Sept. 28, 2026.
U.S. launch preparations target Q4 2026; patient finding cited more than 140 confirmed patients and early-access treatment across 20 specialist centers.
Q1 2026 revenue totaled SEK 13.4 million; cash position was SEK 142.5 million, following a directed share issue of SEK 350 million in April 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Egetis Therapeutics AB (publ) published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Egetis publishes corporate presentation on Emcitate launch, FDA review for MCT8 deficiency drug

You may also like

Crypto prices